This website uses cookies for usage measurement and traffic analysis purposes.
By clicking the "Agree" button or continuing to browse this site, you consent to the use of cookies.
For more details, please refer to the Privacy Policy
(opens in a new window).
After I graduated medical school, I entered in a Ph.D. course of basic pathology lab where I researched tumorigenesis and drug resistance of glioma. Then, I spent two years at Memorial Sloan Kettering Cancer Center as a postdoc and pursuited the molecular target in sarcoma using next-genaration sequencing. I identified that a mutation in MYOD1 gene, a transcription factor regulating the muscle differentiation, is involed in tumorgenesis of sarcoma. After coming back to Japan, I joined Dr. Mano’s lab and started in a study to develop Todai OncoPanel, a cancer panel testing, and the MANO method, a high-throughput functional assay for gene variants.
I am interesed in molecular target identification to progress the new drug development. I am also keen on the construction of new assay using cutting-edge technologies. I am currently building assays for liquid biopsy.
| 2020-Present | Chief, Division of Cellular Signaling, National Cancer Center Research Institute. |
| 2017-2020 | Senior Staff Scientist, Division of Cellular Signaling, National Cancer Center Research Institute. |
| 2015-2017 | Assistant professor, Division of Cellular Signaling, Graduate School of Medicine, The University of Tokyo. |
| 2012-2014 | Fellow, Molecular Pathology & Diagnostics, Memorial Sloan-Kettering Cancer Center, NY. |
| 2011-2012 | Fellow, Department of Cancer Pathology, Hokkaido University Graduate School of Medicine. |
